THE STRATEGY OF PHARMACEUTICAL COMPANIES AND THE ECONOMIC VALUE ADDED

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

SETAYESH M.; DEHGHANI SAADI A.; SALEHINIYA M.; KARAMI Z.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: JOURNAL OF HEALTH ACCOUNTING Year:2015 | Volume:4 | Issue:1 (11) Page(s): 20-36

Download Full-Text

Persian Verion

View:

1,352

Download:

Cites:

Information Journal Paper

Title

THE STRATEGY OF PHARMACEUTICAL COMPANIES AND THE ECONOMIC VALUE ADDED

Author(s)

SETAYESH M. | DEHGHANI SAADI A. | SALEHINIYA M. | KARAMI Z. | Issue Writer Certificate

Keywords

COST LEADING STRATEGYQ2

DIFFERENTIATION STRATEGYQ2

ECONOMIC VALUE ADDEDQ2

Abstract

Introduction: Searching for a prevailing index in evaluating companies is one of the prominent features of the financial researches in the present era. Accordingly, the managers of the companies are trying to establish a new economic framework in their companies for both a better reflection of value and profitability. Hence, choosing an optimal strategy by the managers leads to create a sustainable competitive advantage. Therefore, the aim of this study is to investigate the relationship between the strategy of the pharmaceutical companies listed on the Tehran Stock Exchange and the ECONOMIC VALUE ADDED.Method: This study is an applied research, and it uses a quasi-experimental design by means of ex-post-facto approach. The sample of the research includes 190 observations of the year-end of the company from 2004 to 2013. The data of the research have been tested by Eviews Software Version 8 and by the ordinary least square regression method.Results: The results of the research state that there is a direct and significant relationship between COST LEADING STRATEGY and ECONOMIC VALUE ADDED. But, there is not a significant relationship between DIFFERENTIATION STRATEGY and ECONOMIC VALUE ADDED.Conclusion: The results of the research suggest that the COST LEADING STRATEGY has a significant effect on the improvement of ECONOMIC VALUE ADDED of the pharmaceutical companies listed on the Tehran Stock Exchange. In other words, the managers of the pharmaceutical companies intend to increase the sale by reducing the costs of production.

Cites

No record.

References

No record.

Cite

APA: Copy

SETAYESH, M., DEHGHANI SAADI, A., SALEHINIYA, M., & KARAMI, Z.. (2015). THE STRATEGY OF PHARMACEUTICAL COMPANIES AND THE ECONOMIC VALUE ADDED. JOURNAL OF HEALTH ACCOUNTING, 4(1 (11)), 20-36. SID. https://sid.ir/paper/236400/en

Vancouver: Copy

SETAYESH M., DEHGHANI SAADI A., SALEHINIYA M., KARAMI Z.. THE STRATEGY OF PHARMACEUTICAL COMPANIES AND THE ECONOMIC VALUE ADDED. JOURNAL OF HEALTH ACCOUNTING[Internet]. 2015;4(1 (11)):20-36. Available from: https://sid.ir/paper/236400/en

IEEE: Copy

M. SETAYESH, A. DEHGHANI SAADI, M. SALEHINIYA, and Z. KARAMI, “THE STRATEGY OF PHARMACEUTICAL COMPANIES AND THE ECONOMIC VALUE ADDED,” JOURNAL OF HEALTH ACCOUNTING, vol. 4, no. 1 (11), pp. 20–36, 2015, [Online]. Available: https://sid.ir/paper/236400/en

Related Journal Papers